A Simple, selective, accurate, economical reverse phase high performance liquid chromatography (RP-HPLC) was developed for estimation of Raloxifene in pharmaceutical formulations. Chromatographic separation achieved on a C 18 column (Use INERTSIL, C 18 , 5μ, 250×4.6 mm i.d.) with mobile phase containing acetonirile and ammonium acetate buffer in the ratio 75:25 v/v. The flow rate was 1.0 mL/min and effluent was monitored at 254 nm. The retention time was 4.413 min. The method was validated in terms of linearity, accuracy and precision. The linearity curve was found to be linear over 2.5 -12.5 μg/mL. The limit of detection and limit of quantification were found to be 0.0202 and 0.202 μg/ml respectively. The proposed method was successfully used to determine the drug content of marketed formulations.

Three simple, precise, accurate and economical spectrophotometric methods in ultraviolet and visible region were developed for the determination of faropenem in pure and formulations have been described. The method A is based on the reduction of ferric ion into ferrous ion by the mentioned drug in the presence of 1,10-phenanthroline to form a highly stable orange red colored ferrion complex measured at 510 nm. The method B is based on the oxidation of MBTH with Fe(III) followed by coupling with mentioned drug to form a highly stable violet colored chromogen measured at 610 nm. The method C is based on the reduction of Folin Ciocalteau (FC) reagent in alkaline medium by faropenem leading to the formation of intense blue colored chromogen measured at 740 nm. The results of analysis for all the three methods have been validated statistically and by recovery studies. The proposed methods were simple, sensitive and economical for the quantitative determination of faropenem and were successfully employed for the estimation in pure and in formulations.